These under-appreciated pharma stocks have the potential to become long-term winners.
News & Analysis: Regeneron Pharmaceuticals
This latest pick has been sluggish so far -- but the long-term opportunity may be huge.
But this development could be enormously important in fighting COVID-19.
Issues with timing, delivery, and manufacturing make the treatments less promising.
REGN earnings call for the period ending December 31, 2020.
The big biotech was firing on all cylinders, and getting strong growth out of its top-selling products.
There's some good news and some bad news.
Strong interim trial data boosts the prospects for a treatment already worth billions.
Investors will want to scoop up shares of this diversified drugmaker and coronavirus vaccine developer before it's too late.
This high-growing, blue-chip biotech has just what it takes to make investors rich.